A股異動 | 高瀾股份大升超10% 獲一家三口舉牌
高瀾股份(300499.SZ)再度大幅拉昇升超10%,現報19元續刷階段高價,總市值58.5億元。公司昨日晚間公吿,股東黃澤豐、程銀娥及黃燕霞在10月18日至11月7日期間,在二級市場買入公司股票1729.4萬股股份,佔公司總股本的5.6655%。以高瀾股份在此期間13.77元/股的均價測算,黃澤豐等三人合計買入金額超過2億元。此次舉牌三人是一家人。黃澤豐與程銀娥系母子關係,黃澤豐與黃燕霞系姐弟關係,程銀娥與黃燕霞系母女關係。三人表示,基於對高瀾股份未來發展前景和投資價值的認可,通過二級市場買入的方式增持公司股票。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.